Alcresta Therapeutics Announces FDA Expanded Use Clearance for RELiZORB® (iMMOBILIZED LIPASE) Cartridge for Pediatric Patients 1 Year of Age and Older

WALTHAM, Mass., Jan. 15, 2025 /PRNewswire/ -- Alcresta Therapeutics, Inc., a leading commercial-stage company focused on developing and commercializing novel enzyme-based products, today announced that the U.S. Food and Drug Administration (FDA) has cleared expanded use of RELiZORB® for...